Herantis Pharma Board of Directors’ proposal for dividend

Herantis Pharma Board of Directors’ proposal for dividend

Herantis Pharma Plc.
Company release 27 February 2015 at 5:30 pm

The parent company of Herantis Pharma group is Herantis Pharma Plc whose distributable equity was €25.7 million according to balance sheet 31 December 2014. Herantis Pharma Plc had no revenue in 2014. The financial result of the parent company for 2014 was €-3.5 million.

Herantis was listed on the First North Finland marketplace of NASDAQ OMX Helsinki stock exchange. An Initial Public Offering produced a total of €14.3 million before share issue expenses. The proceeds of the IPO will mainly be used for clinical development of the three main drug candidates of Herantis Pharma group.

The Board of Directors proposes to the Annual General Meeting convening on 9 April 2015 that no dividend for the financial year 2014 will be paid.

Herantis Pharma Plc

Board of Directors

Further information:

Herantis Pharma plc., Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Capital Oy, telephone: +358 9 2538 0225

About Herantis Pharma Plc

Herantis Pharma Plc. is a pharmaceutical company specialised in new drug research and development. The company focuses on diseases with an unmet clinical need. These diseases include for example dry eye syndrome, Parkinson’s disease, and secondary lymphedema. We believe our drugs are the first or best in their class and have the potential to change treatment strategies of diseases. The shares of Herantis Pharma Plc. are listed on the First North Finland marketplace run by NASDAQ Helsinki stock exchange.